WESTFORD, Mass., May 7, 2024
/PRNewswire-PRWeb/ -- Crescent Innovations Inc. announced
today the sale of its technology related to bone regeneration, plus
various intellectual property and know-how assets. Chris Finn, President of the advisory
firm Alternotio announced today that Crescent Innovations has
retained Alternotio to sell the assets using a sealed bid sales
process on June 28, 2024 at
12 PM EDT.
"This technology has been shown to grow
bone rapidly in vivo without induce bone synthesis at ectopic sites
by non-bone cells."
The ability to grow bone at a site-specific location, in a
minimally invasive manner, would have a profound impact on the
health and quality of life for up to 50 million Americans who
suffer bone defects and diseases. These diseases include post
craniotomy resorption, periodontal disease, degenerative disk
disease, osteoporosis, and aseptic osteolysis. Together, these
diseases cost the United States Healthcare System in excess of
$124 billion annually.
Disorder Annual U.S. Cases
Craniotomies 750,000
Periodontal Disease 28,000,000
Spinal Surgeries 1,000,000
Aseptic Osteolysis 500,000
Osteoporosis 3,000,000
Total 33,250,000
The state of the art is Bone Morphogenic Proteins (BMPs) which
are osteogenic compounds. However, BMPs can cause Heterotopic
Ossification (bone growth at non-boney sites) making them somewhat
difficult and risky to use.
The invention comprises a patented osteogenic formulation of
prostaglandin E1, an aleady approved drug, and a delivery system
(HA or Crescent Innovations patented PgGA). This technology has
been shown to grow bone rapidly in vivo without induce bone
synthesis at ectopic sites by non-bone cells.
The assets will be sold at a sealed bid sale on June 28, 2024 at 12 PM
EDT. Parties interested in purchasing any or all of the
assets must sign a confidentiality agreement, which can be obtained
by contacting Chris Finn at
info@alternotio.com or calling +1 (978) 882 - 2586. Negotiated
offers are welcome, but any negotiated sale must be concluded prior
to opening bids on the date specified above and must conform to the
terms set forth for sealed bids.
About Crescent Innovations Inc.
Crescent Innovations Inc. is a firm focused on the development
of biological polymers to create non surgical regenerative
solutions for chronic conditions. The firm currently is focused on
innovating technology to solve TMJ disorders and singular maladies.
If interested in TMJ disorders, please contact Crescent Innovations
directly at www.crescentinnovations.com
About Alternotio.
Alternotio is an advisory firm, that specializes in the sale of
non-lead and distressed intellectual property. Alternotio
occasionally works with unique tangible assets that have a
substantial intellectual property component.
www.alternotio.com
Media Contact
Al Prescott, Crescent Innovations
Inc., 1 978.764.8604, alprescott@crescentinnovations.com,
www.crescentinnovations.com
LinkedIn
View original content to download
multimedia:https://www.prweb.com/releases/crescent-innovations-offers-breakthrough-osteogenic-treatment-technology-for-sale-and-its-impact-on-bone-growth-and-orthopedics-302137835.html
SOURCE Crescent Innovations Inc.